Eden review

Eden advertises compounded semaglutide at $99 a month, and that figure is half the bill. Its own asterisk, printed under every price on the page, says so: "An active Eden Membership is required ($39 for the first month, auto-renews at $99/month thereafter)… Medication is not available without a membership. Membership fee is not included." So the medication is $99 and the membership is another $99, and you cannot buy the first without the second.

In whole numbers, compounded semaglutide costs $198 a month and compounded tirzepatide costs $298 — $199 for the drug plus the same $99 membership. Month one looks cheaper, at $138 and $238, only because the membership is introductory at $39. Anyone comparing Eden's advertised $99 against another provider's all-in monthly rate is comparing half a bill to a whole one.

The disclosure itself deserves credit, though, and it is why this is a caveat rather than an accusation. The membership condition is printed as a footnote beneath every price on the page — not buried in checkout, not hidden behind the intake quiz, and not revealed only on the third screen. Eden also states plainly that there are no long-term contracts: both the membership and the medication bill monthly, and the whole price list renders before you answer a single medical question.

The brand-name lane is real and unusually complete. Ozempic, Zepbound and Mounjaro are each $1,399 a month and Wegovy is $1,695, listed on the same page as the compounded options. Most companies selling compounded GLP-1s either do not offer the approved product or decline to price it; Eden prices all four, which lets a reader see the actual size of the gap between compounded and branded before deciding.

Treat its outcome numbers as marketing. The headline claim of an average 29.3 lb loss in six months rests, by Eden's own footnote, on "self reported data from 111 members" who were also dieting and exercising — a small, unverified, self-selected sample, not a trial result. The "127,000+ members" figure is a company statistic with no published methodology behind it either.

One thing to weigh before you start: Eden Health International Inc. received an FDA warning letter in June 2026, and as of our check on August 7, 2026 it had not been closed out. That is a disclosure rather than a disqualification — the company keeps its place in this ranking and its link is unchanged — but an open letter is a fact worth knowing before you hand over a card, and it is the reason to read the safety information Eden links beside each product rather than skipping past it.